MarketCap
Black Diamond Therapeutics BDTX
$ 1.88
0.53%
Facebook
X
Telegram
Black Diamond Therapeutics Revenue | BDTX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Black Diamond Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70 M | 70 M | 70 M |
Quarterly Revenue Black Diamond Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 70 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70 M | 70 M | 70 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
53 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Clovis Oncology
CLVS
|
36 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Genocea Biosciences
GNCA
|
1.64 M | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
35.9 M | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
70.4 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
223 M | - | - | $ 621 M |  Britain |
 |
Cerus Corporation
CERS
|
234 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
82.5 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.54 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.37 M | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
AbbVie
ABBV
|
16.6 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
2.51 M | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
2.01 M | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
5.82 M | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
205 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
372 M | - | - | - |  Russia |
 |
IMV
IMV
|
188 K | - | - | $ 13.1 M | Canada |
 |
Cardiff Oncology
CRDF
|
593 K | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
882 K | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
654 K | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
9.44 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
312 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
7.7 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
59.4 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
212 K | - | - | $ 756 M | USA |
 |
Cue Biopharma
CUE
|
27.5 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
255 K | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
88 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
1.03 M | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
7.67 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
500 K | $ 7.94 | 1.4 % | $ 373 M | USA |